Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective

References

• US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed May 24, 2022.
   Google Scholar
• Walton MK, Powers JH 3rd, Hobart J, et al. International society for pharmacoeconomics and outcomes research task force for clinical outcomes assessment. clinical outcome assessments: conceptual foundation-report of the ISPOR clinical outcomes assessment - emerging good practices for outcomes research task force. Value Health. 2015;18(6):741–752. doi:10.1016/j.jval.2015.08.006
   PubMed Web of Science ®Google Scholar
• Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematol Am Soc Hematol Educ Program. 2016;2016(1):208–216. doi:10.1182/asheducation-2016.1.208
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Inoue N, Takeda J. Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Adv Immunol. 1995;60:57–103.
   PubMed Web of Science ®Google Scholar
• Parker CJ. Hemolysis in PNH. In: Young NS, Moss J, editors. Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins. San Diego: Academic Press; 2000:49–100.
   Google Scholar
• Inoue N, Izui-Sarumaru T, Murakami Y, et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006;108(13):4232–4236. doi:10.1182/blood-2006-05-025148
   PubMed Web of Science ®Google Scholar
• Endo M, Ware RE, Vreeke TM, et al. Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood. 1996;87(6):2546–2557. doi:10.1182/blood.V87.6.2546.bloodjournal8762546
   PubMed Web of Science ®Google Scholar
• Dezern AE, Borowitz MJ. ICCS/ESCCA consensus guidelines to detect GPI-©deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1—clinical utility. Cytometry B Clin Cytom. 2018;94:16–22. doi:10.1002/cyto.b.21608
   PubMed Web of Science ®Google Scholar
• Gurnari C, Pagliuca S, Patel BJ, et al. Implication of PIGA genotype on erythrocytes phenotype in paroxysmal nocturnal hemoglobinuria. Leukemia. 2021;35(8):2431–2434. doi:10.1038/s41375-020-01113-0
   PubMed Web of Science ®Google Scholar
• Bono E, McLornan D, Travaglino E, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019;33(10):2495–2505. doi:10.1038/s41375-019-0457-1
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Serpenti F, Barcellini W, Caprioli C. Hypoplastic myelodysplastic syndromes: just an overlap syndrome? Cancers. 2021;13(1):132. doi:10.3390/cancers13010132335
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Levati GV, Giannotta JA, et al. Low-risk myelodysplastic syndrome revisited: morphological, autoimmune, and molecular features as predictors of outcome in a single center experience. Front Oncol. 2022;12:795955. doi:10.3389/fonc.2022.795955
   PubMed Web of Science ®Google Scholar
• Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009;373(9665):759–767. doi:10.1016/S0140-6736(09)60001-5
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847. doi:10.1182/blood-2007-06-094136
   PubMed Web of Science ®Google Scholar
• Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552–559. doi:10.1056/NEJMoa031688
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243. doi:10.1056/NEJMoa061648
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained©efficacy and improved survival. Blood. 2011;117(25):6786–6792. doi:10.1182/blood-2011-02-333997
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hochsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373 (11):1032–1039. doi:10.1056/NEJMoa1502950
   PubMed Web of Science ®Google Scholar
• Berzuini A, Montanelli F, Prati D. Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2010;363 (10):993–994. doi:10.1056/NEJMc1005108
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Luzzatto L, Hill A, Kelly R, Hillmen P. Paroxysmal nocturnal hemoglobinuria–hemolysis before and after eculizumab. N Engl J Med. 2010;363(23):2270–2272. doi:10.1056/NEJMc1010351
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094–4100. doi:10.1182/blood-2008-11-189944
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–639. doi:10.1056/NEJMoa1311084
   PubMed Web of Science ®Google Scholar
• Luzzatto L. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria. F1000Res. 2016;23(5):F1000Faculty Rev–209.
   Google Scholar
• Rondelli T, Risitano AM, Pefault de Latour R, et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2014;99(2):262–266. doi:10.3324/haematol.2013.090001
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Röth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73. doi:10.1111/bjh.12347
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Kulasekararaj AG. Second-generation C5 inhibitors for paroxysmal nocturnal hemoglobinuria. BioDrugs. 2020;34:149–158. doi:10.1007/s40259-019-00401-1
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S. Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2018;93:564–577. doi:10.1002/ajh.25016
   PubMed Web of Science ®Google Scholar
• Robert D, Mahon FX, Richard E, Etienne G, de Verneuil H, Moreau-Gaudry FA. SIN lentiviral vector containing PIGA cDNA allows long-term phenotypic correction of CD34+-derived cells from patients with paroxysmal nocturnal hemoglobinuria. Mol Ther. 2003;7:304–316.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540–549. doi:10.1182/blood-2018-09-876805
   PubMed Web of Science ®Google Scholar
• Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci USA. 2019;116:7926–7931. doi:10.1073/pnas.1820892116
   PubMed Web of Science ®Google Scholar
• Maibaum J, Liao SM, Vulpetti A, et al. Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat Chem Biol. 2016;12:1105–1110. doi:10.1038/nchembio.2208
   PubMed Web of Science ®Google Scholar
• Borodovsky A, Yucius K, Sprague A, et al. Development of RNAi therapeutics targeting the complement pathway. Blood. 2013;122:2471. doi:10.1182/blood.V122.21.2471.2471
   Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539. doi:10.1182/blood-2018-09-876136
   PubMed Web of Science ®Google Scholar
• Babushok DV, Stanley N, Xie HM, et al. Clonal replacement underlies spontaneous remission in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2017;176(3):487–490. doi:10.1111/bjh.13963
   PubMed Web of Science ®Google Scholar
• Ferla V, Zaninoni A, Fattizzo B, Fermo E, Gianelli U, Barcellini W. Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission. EurJ Intern Med. 2017;43:e11–e14. doi:10.1016/j.ejim.2017.04.011
   PubMed Web of Science ®Google Scholar
• Gurnari C, Pagliuca S, Kewan T, et al. Is nature truly healing itself? Spontaneous remissions in paroxysmal nocturnal hemoglobinuria. Blood Cancer J. 2021;11(11):187. doi:10.1038/s41408-021-00582-5
   PubMed Web of Science ®Google Scholar
• Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021;112:6522–6527.
   Google Scholar
• Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica. 2012;97(11):1666–1673. doi:10.3324/haematol.2012.062828
   PubMed Web of Science ®Google Scholar
• Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985–4996. doi:10.1182/blood-2012-09-311381
   PubMed Web of Science ®Google Scholar
• Gurnari C, Colak C, Zawit M, Maciejewski JP. Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria. Lancet. 2021;398 (10304):e14. doi:10.1016/S0140-6736(21)01542-7
   PubMed Web of Science ®Google Scholar
• Plessier A, Esposito-Farèse M, Baiges A, et al. Paroxysmal nocturnal hemoglobinuria and vascular liver disease: eculizumab therapy decreases mortality and thrombotic complications. Am J Hematol. 2022;97(4):431–439. doi:10.1002/ajh.26474
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Dunlop A, Ireland RM, et al. Prognostic and predictive impact of small PNH clones in a large cohort of patients with myelodysplastic syndromes and aplastic anemia: a single-center experience. Blood. 2018;132:3870. doi:10.1182/blood-2018-99-116772
   Web of Science ®Google Scholar
• The WHOQOL Group. World health organization quality of life assessment. What quality of life? World Health Forum. 1996;17(4):354–356.
   PubMedGoogle Scholar
• Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020;26(12–bSuppl):S8–S14. doi:10.18553/jmcp.2020.26.12-b.s8
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Röth A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505–1514. doi:10.1007/s00277-020-04052-z
   PubMed Web of Science ®Google Scholar
• Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79. doi:10.1186/1477-7525-1-79
   PubMedGoogle Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European-Organization-for-Research-and-Treatment-of-Cancer QLQ-C30 – a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. doi:10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Daly RP, Jalbert JJ, Keith S, Symonds T, Shammo J. A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ. J Patient Rep Outcomes. 2021;5(1):102. doi:10.1186/s41687-021-00376-0
   PubMedGoogle Scholar
• Groth M, Singer S, Niedeggen C, et al. Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. Ann Hematol. 2017;96(2):171–181. doi:10.1007/s00277-016-2867-8
   PubMed Web of Science ®Google Scholar
• Kaiser K, Yount SE, Martens CE, et al. Assessing preferences for rare disease treatment: qualitative development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ©). Patient Prefer Adherence. 2020;5(14):705–715. doi:10.2147/PPA.S233830
   Web of Science ®Google Scholar
• Schubert J, Hillmen P, Röth A, et al.; TRIUMPH Study Investigators. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2008;142(2):263–272. doi:10.1111/j.1365-2141.2008.07183.x
   PubMed Web of Science ®Google Scholar
• Ueda Y, Obara N, Yonemura Y, et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2018;107(6):656–665. doi:10.1007/s12185-018-2409-3
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Langemeijer S, et al. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. Eur J Haematol. 2021;106(3):389–397. doi:10.1111/ejh.13564
   PubMed Web of Science ®Google Scholar
• Peipert JD, Kulasekararaj AG, Gaya A, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020;15(9):e0237497. doi:10.1371/journal.pone.0237497
   PubMed Web of Science ®Google Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037. doi:10.1056/NEJMoa2029073
   PubMed Web of Science ®Google Scholar
• Röth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020;135(12):912–920. doi:10.1182/blood.2019003399
   PubMed Web of Science ®Google Scholar
• Risitano AM, Kulasekararaj AG, Lee JW, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(12):3188–3197. doi:10.3324/haematol.2020.261826
   PubMed Web of Science ®Google Scholar
• Kulasekararaj G, Risitano AM, Maciejewski JP, et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021;138(20):1928–1938. doi:10.1182/blood.2021011388
   PubMed Web of Science ®Google Scholar
• Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021;8(5):e344–e354.doi:10.1016/S2352-3026(21)00028-4
   PubMed Web of Science ®Google Scholar
• Jang JH, Wong LL, Ko BS, et al. 12-month analysis of a Phase 2 study of iptacopan (LNP023) monotherapy for paroxysmal nocturnal hemoglobinuria. Presented at ASH. Atlanta; 2021.
   Google Scholar